Lafayette Investments Inc. lowered its holdings in Johnson & Johnson (NYSE:JNJ) by 2.2% in the first quarter, Holdings Channel.com reports. The fund owned 36,982 shares of the company’s stock after selling 836 shares during the quarter. Johnson & Johnson makes up 2.3% of Lafayette Investments Inc.’s investment portfolio, making the stock its 11th largest position. Lafayette Investments Inc.’s holdings in Johnson & Johnson were worth $4,849,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in JNJ. Norges Bank acquired a new stake in Johnson & Johnson in the fourth quarter valued at $4,139,107,000. Amundi Pioneer Asset Management Inc. raised its stake in shares of Johnson & Johnson by 77.4% during the 4th quarter. Amundi Pioneer Asset Management Inc. now owns 4,725,664 shares of the company’s stock worth $689,332,000 after buying an additional 2,061,958 shares during the last quarter. M&G Investment Management Ltd. acquired a new position in shares of Johnson & Johnson during the 4th quarter worth $269,234,000. Alliancebernstein L.P. raised its stake in shares of Johnson & Johnson by 20.5% during the 4th quarter. Alliancebernstein L.P. now owns 9,399,325 shares of the company’s stock worth $1,371,080,000 after buying an additional 1,599,581 shares during the last quarter. Finally, Geode Capital Management LLC raised its stake in shares of Johnson & Johnson by 3.7% during the 4th quarter. Geode Capital Management LLC now owns 38,393,079 shares of the company’s stock worth $5,589,167,000 after buying an additional 1,364,028 shares during the last quarter. 67.66% of the stock is owned by institutional investors.

Johnson & Johnson stock opened at $144.37 on Friday. The company has a current ratio of 1.31, a quick ratio of 1.05 and a debt-to-equity ratio of 0.41. The stock has a market cap of $386.52 billion, a PE ratio of 19.10, a P/E/G ratio of 3.19 and a beta of 0.71. The stock has a 50-day moving average price of $146.81 and a 200 day moving average price of $142.30. Johnson & Johnson has a 52 week low of $109.16 and a 52 week high of $157.00.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, April 14th. The company reported $2.30 EPS for the quarter, beating the consensus estimate of $2.03 by $0.27. The company had revenue of $20.69 billion during the quarter, compared to analysts’ expectations of $19.48 billion. Johnson & Johnson had a return on equity of 39.71% and a net margin of 24.47%. The firm’s revenue was up 3.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.10 EPS. On average, equities analysts predict that Johnson & Johnson will post 7.68 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 9th. Shareholders of record on Tuesday, May 26th will be issued a $1.01 dividend. This is a boost from Johnson & Johnson’s previous quarterly dividend of $0.95. The ex-dividend date of this dividend is Friday, May 22nd. This represents a $4.04 annualized dividend and a yield of 2.80%. Johnson & Johnson’s payout ratio is 43.78%.

JNJ has been the subject of several research reports. SVB Leerink cut their price target on Johnson & Johnson from $172.00 to $160.00 and set an “outperform” rating for the company in a research note on Wednesday, April 8th. Bank of America raised Johnson & Johnson from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $150.00 to $175.00 in a research note on Wednesday, April 22nd. Argus reaffirmed a “buy” rating and set a $155.00 price target (down previously from $165.00) on shares of Johnson & Johnson in a research note on Friday, March 27th. UBS Group downgraded Johnson & Johnson from a “buy” rating to a “neutral” rating and cut their price target for the stock from $163.00 to $160.00 in a research note on Tuesday, April 28th. Finally, Citigroup lifted their price objective on Johnson & Johnson from $150.00 to $165.00 and gave the stock a “buy” rating in a research report on Wednesday, April 15th. Four investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $163.47.

In other Johnson & Johnson news, Director William D. Perez purchased 500 shares of the stock in a transaction on Friday, March 13th. The stock was bought at an average price of $127.69 per share, for a total transaction of $63,845.00. Following the acquisition, the director now directly owns 16,030 shares of the company’s stock, valued at $2,046,870.70. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 0.27% of the stock is owned by insiders.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

See Also: Front-End Load

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.